A. R. Norman

460 total citations
15 papers, 173 citations indexed

About

A. R. Norman is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. R. Norman has authored 15 papers receiving a total of 173 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Surgery and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. R. Norman's work include Colorectal Cancer Treatments and Studies (6 papers), Colorectal and Anal Carcinomas (3 papers) and Gastric Cancer Management and Outcomes (3 papers). A. R. Norman is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Colorectal and Anal Carcinomas (3 papers) and Gastric Cancer Management and Outcomes (3 papers). A. R. Norman collaborates with scholars based in United Kingdom, Australia and United States. A. R. Norman's co-authors include David Cunningham, J. Oates, M. Nicolson, Timothy Iveson, Naureen Starling, Gary Middleton, Sujaya Rao, F. Daniel, Fareeda Y. Coxon and Cynthia Aranow and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

A. R. Norman

15 papers receiving 163 citations

Peers

Countries citing papers authored by A. R. Norman

Since Specialization

Citations

This map shows the geographic impact of A. R. Norman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. R. Norman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. R. Norman more than expected).

Fields of papers citing papers by A. R. Norman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. R. Norman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. R. Norman. The network helps show where A. R. Norman may publish in the future.

Co-authorship network of co-authors of A. R. Norman

This figure shows the co-authorship network connecting the top 25 collaborators of A. R. Norman. A scholar is included among the top collaborators of A. R. Norman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. R. Norman. A. R. Norman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee 2024 ·PharmacoEconomics ·(unknown), A. R. Norman, Martin Hoyle, Sean Lybrand, Bonny Parkinson	2
2	Improving emergency department care for adults presenting with mental illness: a systematic review of strategies and their impact on outcomes, experience, and performance 2024 ·Frontiers in Psychiatry ·Elizabeth Austin, Colleen Cheek, (unknown), Luke Testa, Amanda Dominello, Janet C. Long, Ann Carrigan, Louise A. Ellis, A. R. Norman, Margaret Murphy, (unknown), Donna Gillies, Robyn Clay‐Williams	3
3	Cost of Illness and Health-Related Quality of Life for Stuttering: Two Systematic Reviews 2023 ·Journal of Speech Language and Hearing Research ·A. R. Norman, Robyn Lowe, Mark Onslow, Sue O’Brian, Ann Packman, Ross G. Menzies, Liz Schroeder	8
4	The NUT study: the effect of dietetic and oral nutritional interventions on survival and quality of life in patients with weight loss undergoing palliative chemotherapy for gastrointestinal (GI) or lung malignancy, a randomised controlled trial 2008 ·Proceedings of The Nutrition Society ·Christine Baldwin, A. Spiro, C. McGough, A. R. Norman, (unknown), David Cunningham, Jervoise Andreyev	4
5	The NUT study: the effect of dietetic and oral nutritional interventions on survival and quality of life in patients with weight loss undergoing palliative chemotherapy for gastrointestinal (GI) or lung malignancy, a randomised controlled trial 2008 ·Proceedings of The Nutrition Society ·Christine Baldwin, A. Spiro, C. McGough, A. R. Norman, Mary O’Brien, David Cunningham, Jervoise Andreyev	6
6	Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial 2006 ·Journal of Clinical Oncology ·David Cunningham, Sujaya Rao, Naureen Starling, Timothy Iveson, M. Nicolson, Fareeda Y. Coxon, Gary Middleton, F. Daniel, J. Oates, A. R. Norman	77
7	Gemcitabine (GEM), cisplatin (P) and methylprednisolone: A salvage regimen in relapsed Hodgkin's disease and non-Hodgkin's lymphoma 2004 ·Journal of Clinical Oncology ·Justin S. Waters, Ian Chau, A. R. Norman, M Pollard, A. Wotherspoon, David Cunningham	1
8	Elderly patients with fluoropyrimidine-resistant advanced colorectal cancer (CRC) derive similar benefit without excessive toxicity when treated with irinotecan monotherapy 2004 ·Journal of Clinical Oncology ·(unknown), Ian Chau, A. R. Norman, (unknown), (unknown), Gary Middleton, Mark Hill, Paul J. Ross, J. Oates, David Cunningham	1
9	A randomised comparison between six months of bolus fluorouracil (5-FU)/leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5-FU as adjuvant treatment in colorectal cancer: An update with 5 years' follow-up 2004 ·Journal of Clinical Oncology ·Naureen Starling, Ian Chau, A. R. Norman, (unknown), Timothy Iveson, Mark Hill, Tamas Hickish, F. Lofts, (unknown), David Cunningham	1
10	randomised, multicenter phase-iii study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: Confirmation of dose escalation : 1031 2003 ·Kate Sumpter, Catherine Harper‐Wynne, David Cunningham, J. Oates, (unknown), Timothy Iveson, M. Nicolson, Tamas Hickish, (unknown), A. R. Norman	18
11	Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex®) in advanced colorectal cancer 1998 ·European Journal of Cancer ·David Farrugia, A. R. Norman, David Cunningham	5
12	5-Fluorouracil and mitomycin-C in colorectal cancer: Unacceptable conclusion 1998 ·Annals of Oncology ·Paul J. Ross, A. R. Norman, David Cunningham	1
13	A prospective randomlsed trial of protracted venous infusion (PVI) 5-FU with or without mitomycin C (MMC) in advanced colorectal cancer 1997 ·European Journal of Cancer ·Paul J. Ross, A. R. Norman, David Cunningham, A. Webb, Timothy Iveson, Anwar R. Padhani, Alison Massey	2
14	Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. 1997 ·PubMed ·Cynthia Aranow, Steven B. Zelicof, Denise Leslie, (unknown), Peter Barland, A. R. Norman, (unknown), Arthur Weinstein	43
15	236Hypofractionated radiotherapy for primary carcinoma of the bladder in geriatric patients 1996 ·Radiotherapy and Oncology ·A. Horwich, Caroline José, Anna Price, A. R. Norman, G. Jay, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact